ALLO:NSD-Allogene Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 10.80

Change

+0.48 (+4.65)%

Market Cap

USD 1.48B

Volume

1.49M

Avg Analyst Target

USD 22.44 (+107.82%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ALLO Stock Forecast & Price:
Based on the Allogene Therapeutics Inc stock forecasts from 8 analysts, the average analyst target price for Allogene Therapeutics Inc is USD 22.44 over the next 12 months. Allogene Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Allogene Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Allogene Therapeutics Inc’s stock price was USD 10.80. Allogene Therapeutics Inc’s stock price has changed by +1.69% over the past week, -20.70% over the past month and -57.98% over the last year.

About Allogene Therapeutics Inc (ALLO:NSD)

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-2.95 (-0.43%)

USD76.14B 13.80 10.63
VRTX Vertex Pharmaceuticals Inc

-3.26 (-1.11%)

USD73.02B 23.28 15.15
MRNA Moderna Inc

+0.18 (+0.15%)

USD46.19B 3.66 2.45
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+1.28 (+0.96%)

USD30.98B 2.87 1.32
RPRX Royalty Pharma Plc

-0.15 (-0.37%)

USD27.19B 39.06 19.32
SGEN Seagen Inc

+1.13 (+0.83%)

USD25.40B 55.02 -36.47
ALNY Alnylam Pharmaceuticals Inc

-9.23 (-4.41%)

USD25.13B N/A -31.40
GMAB Genmab AS

+0.20 (+0.63%)

USD21.66B 41.88 3.47
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ALLO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.61% 73% C 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.61% 73% C 50% F
Trailing 12 Months  
Capital Gain -55.95% 60% D- 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.95% 60% D- 33% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.58% 46% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.58% 46% F 24% F
Risk Return Profile  
Volatility (Standard Deviation) 37.38% 63% D 42% F
Risk Adjusted Return -25.62% 48% F 34% F
Market Capitalization 1.48B 89% B+ 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.90 48% F 40% F
Price / Cash Flow Ratio -8.03 76% C 68% D+
EV/EBITDA -3.86 76% C 73% C
Management Effectiveness  
Return on Equity -33.71% 77% C+ 36% F
Return on Invested Capital -25.63% 76% C 34% F
Return on Assets -18.57% 74% C 27% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 14.77 12% F 5% F
Short Percent 24.52% 3% F 5% F
Beta 0.52 80% B- 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.